Cancer Reports (Feb 2022)

Neoadjuvant lenvatinib for inoperable thyroid cancer: A case report and literature review

  • Khalid Alshehri,
  • Yousuf Alqurashi,
  • Mazin Merdad,
  • Shaza Samargandy,
  • Razan Daghistani,
  • Hani Marzouki

DOI
https://doi.org/10.1002/cnr2.1466
Journal volume & issue
Vol. 5, no. 2
pp. n/a – n/a

Abstract

Read online

Abstract Background Poorly differentiated thyroid cancer (PDTC) is now classified as a separate thyroid tumor entity. It has male predominance and poor prognosis compared to differentiated TC. Case We report a case of a patient with PDTC who was previously deemed inoperable. A trial of neoadjuvant lenvatinib therapy was given to the patient after that the tumor become operable and the surgery went successfully. Conclusions Lenvatinib is a feasible option in patients with inoperable TC and can stabilize the lesion size or even reduce it, leading to a more favorable surgical outcome.

Keywords